Analyst predicts Eli Lilly will dominate obesity and diabetes next year
Four weeks since it was launched, Zepbound has generated weekly growth of more than 192%.
AF MARKETWIRE
US pharmaceutical giant Eli Lilly - whose shares are on track for a seventh straight year of annual gains of more than 10% - looks set to dominate the landscape for GLP-1 drugs to treat obesity and diabetes next year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk's popularity declining among portfolio managers
For subscribers
